BTIG just kicked off coverage on Tempus AI (NASDAQ:TEM) with a Buy rating and a $60 price target suggesting nearly 48% upside from where the stock trades now. Analyst Mark Massaro called the ...

Tempus AI grew revenue 30.4% YoY in FY2024 to $693.4M, with Q4 growth at 35.8%. Genomics drove 65% of FY2024 revenue at $451.7M with a suboptimal 49.2% gross margin and cost-intensive delivery ...

Tempus AI is trading near yearly lows despite strong growth prospects, driven by the Ambry Genetics acquisition and robust organic growth. The company has innovative AI diagnostic services ...

Tempus AI has a 12-month low of $22.89 and a 12-month high of $91.45. Insider Activity at Tempus AI In related news, CEO Eric P. Lefkofsky sold 476,209 shares of the firm’s stock in a ...

Illumina and Tempus AI have partnered to drive clinical adoption of next-generation sequencing tests beyond oncology, the companies said Tuesday. The collaborators will combine Illumina’s ...

BTIG analyst Mark Massaro has initiated coverage on Tempus AI (TEM), with a Buy rating and a price target of $60, implying 48.3% upside potential. The analyst views TEM’s AI applications and ...

Tempus Unveils Advisory Board Featuring Leading Physicians From Across the U.S. Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and ...

Investors with a lot of money to spend have taken a bullish stance on Tempus AI TEM. And retail traders should know. We noticed this today when the positions showed up on publicly available ...

Illumina is teaming up with Tempus AI for a project aimed at promoting the use of DNA sequencing tests across all major areas of disease. The companies said they will work together to train ...

Illumina (ILMN) and Tempus AI (TEM) announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence generation. The collaboration will combine ...

The Tempus 2 is the second iteration of Saucony’s niche, support-meets-speed offering. True to its name, it’s a shoe that (on paper at least) is as much geared up for tempo sessions and ‘go ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is scheduled to exhibit 4 abstracts at ...